the aid library

LIST OPTIONS

Filter

4872

Screening donated blood for transfusion-transmissible infections: recommendations

World Health Organization (WHO) (2009) C_WHO

The provision of safe and efficacious blood and blood components for transfusion or manufacturing use involves a number of processes, from the selection of blood donors and the collection, processing and testing of blood donations to the testing of patient samples, the issue of compatible blood and ... more

External Link

Future of Nursing 2020-2030

Wakefield, M.K.; et al. National Academy of Medicine; National Academies of Sciences, Engineering, and Medicine (2021) C1

Charting a Path to Achieve Health Equity. The decade ahead will test the nation's nearly 4 million nurses in new and complex ways. Nurses live and work at the intersection of health, education, and communities. Nurses work in a wide array of settings and practice at a range of professional levels. T... more

Download (900)

View PDF (1501)

Guide for local adaptation - Guidelines for an Integrated Approach to the Nutritional care of HIV-infected children (6 months-14 years)

World Health Organization WHO (2009)

In the area of nutrition and HIV, children deserve special attention because of their additional needs to ensure growth and development and their dependency on adults for adequate care. It was therefore proposed to first develop guidelines for children and thereafter consider a similar approach for... more

Download (513)

View PDF (425)

Recommendations for Implementing Antimicrobial Stewardship Programs in Latin America and the Caribbean: Manual for Public Health Decision-Makers

Pan American Health Organization PAHO (2018) C2

As a public good, antimicrobial medicines require rational use if their effectiveness is to be preserved. However, up to 50% of antibiotic use is inappropriate, adding considerable costs to patient care, and increasing morbidity and mortality. In addition, there is compelling evidence that antimicro... more

Download (298)

View PDF (349)

Climate change and health: vulnerability and adaptation assessment (Update)

World Health Organization WHO; PAHO; et al. (2021) C_WHO

In 2013 the World Health Organization (WHO) published the report Protecting health from climate change:vulnerability and adaptation assessment. The aim was to provide basic and flexible guidance on conducting national or subnational assessments of current and future vulnerability (the susceptibilit... more

Download (391)

View PDF (486)

Operational manual on leishmaniasis vector control, surveillance, monitoring and evaluation

World Health Organisation (WHO) (2023) C_WHO

Despite the significant role of vector control in national leishmaniasis control programmes, the programmatic community perceives vector control as the weakest component of leishmaniasis control strategies in terms of resources, scientific evidence of the usefulness of interventions and capacity for... more

Download (419)

View PDF (630)

The Premium Counselling Relationship Manual

N. Chowdhary, H. Dabholkar; R. Velleman, et al. Sangath; London School of Hygiene & Tropical Medicine (2013) CC

his manual is for people who have had no formal training in counselling but wish to learn the necessary components to establishing an effective counselling relationship. It will be useful for anyone who is involved in counselling people with a mental health problem. h... more

Download (251)

View PDF (506)

Supporting improvement of infection prevention and control programmes at national and facility levels in Ukraine during the COVID-19 pandemic in 2020: report

World Health Organization WHO, Regional Office of Europe (2021) CC

This report offers a summary of the provided support and recommendations on priority activities for IPC improvement at national and facility levels. The COVID-19 pandemic spotlighted areas for improvement in the IPC programme at national and facility levels. Improvements in the IPC programme were ac... more

Download (369)

View PDF (351)

Understanding modelling approaches for sexual, reproductive, maternal, newborn, child and adolescent health, and nutrition

World Health Organization WHO; UNICEF and UNFPA (2021) C_WHO

Modelling the health impacts of disruptions to essential health services during COVID-19 Module 1 Several epidemiological models have been created to assess the potential impact of disruptions to essential health services caused by COVID-19 on morbidity and mortality from conditions other than COVI... more

Download (433)

View PDF (546)

Infection prevention and control in the context of coronavirus disease (‎COVID-19)‎: a living guideline, 13 January 2023

World Health Organisation (WHO) (2023) C_WHO

The WHO continuously reviews available data on SARS-CoV-2 variants of concern. For this version, the global epidemiological situation of the COVID-19 pandemic as of 21 January 2022 – at a time when the Omicron VOC had been identified in 171 countries across all six WHO Regions and was rapidly re... more

Download (430)

View PDF (369)

Guidance and technical packages on community mental health services: promoting person-centred and rights-based approaches

World Health Organization WHO (2021) C_WHO

The WHO Guidance on community mental health services: Promoting person-centred and rights-based approaches document is part of the WHO Guidance and technical packages on community mental health services set of publications. It provides a detailed description of person-centred and human rights-based ... more

Download (471)

View PDF (807)

Global spending on health: Weathering the storm

World Health Organization WHO (2020) C_WHO

The 2020 Report analyzes global health spending for 190 countries from 2000 to 2018 and provides insights as to the health spending trajectory from the MDG era to the SDG era prior to the crisis of 2020. The report shows that global spending on health continually rose between 2000 and 2018 and reach... more

Download (514)

View PDF (734)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (469)

View PDF (683)

Leveraging the Learning Insights from HIV Programming for Pregnant and Parenting Adolescent Girls

UN Children's Fund UNICEF (2023) CC

Pregnancy and childbirth during adolescence profoundly affects the lives of millions of girls worldwide, and is a leading cause of maternal mortality and morbidity, and infant and child mortality. Every year, an estimated 21 million girls aged 15–19 years old in low- and middle-income countries be... more

Download (289)

View PDF (352)

Prevention and control of noncommunicable diseases in Turkey - The case for investment

Kontsevaya A, Farrington J, Balcılar M, Ergüder T World Health Organization (2018) C_WHO

Noncommunicable diseases (NCDs) such as cancer, cardiovascular diseases, diabetes and chronic respiratory diseases and their risk factors are an increasing public health and development challenge in Turkey. This report provides evidence through three analyses that NCDs reduce economic output, and di... more

Download (174)

View PDF (142)

Intestinal schistosomiasis of Ijinga Island, north-western Tanzania: prevalence, intensity of infection, hepatosplenic morbidities and their associated factor

Mueller, A.; A. Fuss, U. Ziegler, et al. (2019) CC

BMC Infectious Diseases (2019) 19:832 Intestinal schistosomiasis is highly endemic in Tanzania and mass drug administration (MDA) using praziquantel is the mainstay of the control program. However, the MDA program covers only school aged children and does not include neither adult individuals nor... more

Download (323)

View PDF (400)

Coronavirus SARS-CoV-2/ COVID-19 Pandemic: Information and interim guidelines for pharmacists and the pharmacy workforce

International Pharmaceutical Federation (FIP) (2020) CC

The purpose of this document is to provide relevant information and guidelines on coronavirus outbreaks – and in particular the novel coronavirus SARS-CoV-2 and the diseases it produces, COVID-19 – for pharmacists and the pharmacy workforce, both in a primary care context (i.e. community phar... more

Download (451)

View PDF (394)

Infection prevention and control in the context of coronavirus disease (‎COVID-19)‎: a living guideline, 9 October 2023

World Health Organization WHO (2023) CC

The Infection prevention and control in the context of coronavirus disease 2019 (COVID-19): a living guideline consolidates technical guidance developed and published during the COVID-19 pandemic into evidence-informed recommendations for infection prevention and control (IPC). This living guideline... more

Download (315)

View PDF (229)

Preventing HIV misdiagnosis: implementation guide

World Health Organization WHO (2024) CC

HIV testing programmes need to ensure that all clients who test for HIV are provided with correct diagnoses. The accuracy of HIV testing is critical to prevent misdiagnosis, as the consequences of giving an incorrect test result can be serious for clients, HIV testing services, HIV programmes and pu... more